Drug intelligence / Profile preview

CHR-101

Development stage: Preclinical
Lead developer: Chromista
Modality: Small Molecules

Overview

CHR-101 is an investigational small‑molecule inhibitor of covalently closed circular DNA (cccDNA), being developed as a potentially curative therapy for chronic hepatitis B virus (HBV) infection. By directly targeting HBV cccDNA, which serves as the stable nuclear template for viral replication and persistence, CHR-101 aims to durably suppress or eradicate viral reservoirs beyond what is achievable with current nucleos(t)ide analogues. The program originates from Chromis Therapeutics, a San Diego–based biopharmaceutical company focused on curative therapies for chronic HBV, and is currently in preclinical development as a first-in-class cccDNA-directed antiviral agent.[3][5][7]

Targets

cccDNA (Hepatitis B virus covalently closed circular DNA)

Beyond the preview

Go deeper on CHR-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHR-101.

Explore the full profile